302 related articles for article (PubMed ID: 24832199)
41. Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels.
Zhang X; Zhong Y; Saad F; Haider KS; Haider A; Clendenin AG; Xu X
Aging Male; 2020 Jun; 23(2):112-118. PubMed ID: 30857458
[No Abstract] [Full Text] [Related]
42. Investigating the basis of sexual dysfunction during late-onset hypogonadism.
Tharakan T; Miah S; Jayasena C; Minhas S
F1000Res; 2019; 8():. PubMed ID: 30984376
[TBL] [Abstract][Full Text] [Related]
43. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.
Michaud JE; Billups KL; Partin AW
Ther Adv Urol; 2015 Dec; 7(6):378-87. PubMed ID: 26622322
[TBL] [Abstract][Full Text] [Related]
44. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
45. Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism.
Yamaguchi K; Ishikawa T; Chiba K; Fujisawa M
Andrologia; 2011 Feb; 43(1):52-6. PubMed ID: 21219383
[TBL] [Abstract][Full Text] [Related]
46. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
47. Testosterone replacement therapy in patients with cachexia: a contemporary review of the literature.
Tabei SS; Kataria R; Hou S; Singh A; Al Hameedi H; Hasan D; Hsieh M; Raheem OA
Sex Med Rev; 2024 Jun; 12(3):469-476. PubMed ID: 38757386
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of testosterone replacement therapy for treating metabolic disturbances in late-onset hypogonadism: a systematic review and meta-analysis.
Kim SH; Park JJ; Kim KH; Yang HJ; Kim DS; Lee CH; Jeon YS; Shim SR; Kim JH
Int Urol Nephrol; 2021 Sep; 53(9):1733-1746. PubMed ID: 34089171
[TBL] [Abstract][Full Text] [Related]
49. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
[TBL] [Abstract][Full Text] [Related]
50. Testosterone replacement therapy following radical prostatectomy.
Khera M; Grober ED; Najari B; Colen JS; Mohamed O; Lamb DJ; Lipshultz LI
J Sex Med; 2009 Apr; 6(4):1165-1170. PubMed ID: 19207277
[TBL] [Abstract][Full Text] [Related]
51. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.
Curran MJ; Bihrle W
Urology; 1999 Feb; 53(2):423-4. PubMed ID: 9933071
[TBL] [Abstract][Full Text] [Related]
52. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
53. Androgen replacement in men undergoing treatment for prostate cancer.
Rhoden EL; Averbeck MA; Teloken PE
J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
[TBL] [Abstract][Full Text] [Related]
54. Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa.
Zhang X; Zhong Y; Saad F; Haider K; Haider A; Xu X
World J Urol; 2019 Oct; 37(10):2091-2097. PubMed ID: 30659301
[TBL] [Abstract][Full Text] [Related]
55. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
[TBL] [Abstract][Full Text] [Related]
56. The effects of testosterone replacement therapy on the prostate: a clinical perspective.
Miah S; Tharakan T; Gallagher KA; Shah TT; Winkler M; Jayasena CN; Ahmed HU; Minhas S
F1000Res; 2019; 8():. PubMed ID: 30828436
[TBL] [Abstract][Full Text] [Related]
57. Testosterone therapy and prostate carcinoma.
Rhoden EL; Averbeck MA
Curr Urol Rep; 2009 Nov; 10(6):453-9. PubMed ID: 19863857
[TBL] [Abstract][Full Text] [Related]
58. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany.
Kühn CM; Strasser H; Romming A; Wullich B; Goebell PJ
Urol Int; 2015; 95(2):153-9. PubMed ID: 25677365
[TBL] [Abstract][Full Text] [Related]
59. Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk.
Maganty A; Osterberg EC; Ramasamy R
Am J Mens Health; 2015 Jul; 9(4):340-4. PubMed ID: 24972716
[TBL] [Abstract][Full Text] [Related]
60. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy.
Ide V; Vanderschueren D; Antonio L
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
